Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Power of Prescription Drug Monitoring Programs (PDMP) in an American Health Crisis

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction to prescription painkillers. In response to the serious public health problem in this country, efforts are underway to combat this growing threat. One solution is the advent of Prescription Drug Monitoring Programs (PDMP).

What is a PDMP?

PDMP is a healthcare tool with a variety of applications. The first PDMP appeared in California in 1939, primarily as a benefit for law enforcement tracking illegal drug behaviors. Today’s PDMP has evolved; as an online database of prescribing and dispensing data, PDMP helps identify when a patient obtains multiple prescriptions from different practitioners. Each database is state-run and used to address prescription drug diversion and abuse. PDMPs serve multiple functions. A PDMP is a patient care tool, a drug epidemic early warning system, and a drug diversion and insurance fraud investigation mechanism. The goal of the PDMP is to reduce the impact of prescription drug abuse and diversion.

Areas of Current and Future PDMP Impact

Not all states have PDMP requirements. Those who currently require health care personnel to utilize this system are Arizona, Connecticut, Maine, Minnesota, New York, Virginia, North Carolina, and Rhode Island. These states are seeing drastically reduced incidences of fraudulent patient behavior.

This is especially true in highly populated states such as New York, where improved visibility into prescribing patterns and potential drug-seeking behaviors has been critical to combating the practice of “doctor shopping,” as described above, in which drug addicts and system abusers go from clinic to clinic amassing a pile of prescriptions for the desired controlled substances. Looking toward the future, 12 states have requirements pending, and the hope is that the 29 states plus DC and Guam who currently have no requirement will decide to follow suit soon.

New York’s successful program has expanded to include access to other state databases and information, and this transparency and interoperability might be a prediction of the future of PDMP.

Overall Benefits

Data regarding PDMP use by state clearly shows positive benefits in the states that use these tools. While research into PDMP effectiveness is ongoing, a 2012 study looked at rates of painkiller abuse and misuse in PDMP vs. non-PDMP states from 2003 to 2009 and discovered that in non-PDMP states, rates of abuse and misuse increased more rapidly than in states with such programs.

But PDMPs are not just concerned with legality. Hand-in-hand with reduced fraudulent and abusive behavior is the improvement of identification of and treatment options for those spiraling in the tornado of the addiction epidemic, perhaps the real crowning achievement of these programs. A hallmark of addiction is a lack of self-awareness and honesty regarding one’s own harmful behaviors, and the PDMP becomes a life-saving tool in which doctors and patients can have the transparent conversations needed to kick-start recovery.

DrFirst and ChartLogic

DrFirst has been at the forefront of electronic prescribing of controlled substances (EPCS) since it sent the nation’s first electronic prescription of a controlled substance. In our partnership with DrFirst, ChartLogic is poised to make a huge impact on this current health crisis as part of a joint effort. The marriage of our software with DrFirst’s program makes sense given the proven success of our ambulatory EHR suite that includes Electronic Medical Records, Practice Management, and Billing Services. And we are proud to be part of a solution that is not only changing lives, but also saving them

Read more at chartlogic.com

Sources:

http://www.chartlogic.com/blog/the-power-of-prescription-drug-monitoring-programs/#_ednref1

https://www.ncjrs.gov/pdffiles1/ondcp/pdmp.pdf

https://searchandrescueusa.org/monitoryourpatients/?utm_source=google&utm_medium=ppc&utm_campaign=2018_PFDK_Nonbrand_PDMP&utm_term=pdmp

https://healthitanalytics.com/news/ny-expands-prescription-drug-monitoring-program-to-25-states

https://www.drugrehab.org/the-benefits-of-prescription-drug-monitoring-programs-pdmp/

https://www.drfirst.com/resources/e-prescribing-mandate-map/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512